Research progress in the influence of EGFR genovariation on the clinical efficacy of gefitinib treatment of non-small cell lung cancer
As an epidermal growth factor receptor (EGFR) tyrosine kinase lung cancer-targeted drug, gefitinib has been widely applied in the treatment of non-small cell lung cancer (NSCLC). The present clinical application has shown that EGFR genovariation might cause the abnormal expression of lung cancer...
Main Authors: | Yang Wang, Jiang Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Board of Journal of Hainan Medical University
2018-02-01
|
Series: | Journal of Hainan Medical University |
Subjects: | |
Online Access: | http://www.hnykdxxb.com/PDF/201802/39.pdf |
Similar Items
-
Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01) -
EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01) -
Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01) -
Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01) -
Correlation between DAPK Promoter Methylation and Gefitinib Sensitivity in Non-small Cell Lung Cancer
by: Weiqin Wu, et al.
Published: (2013-12-01)